Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 3Phase EARLY_PHASE1 2Phase 4 2Phase 2/3 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Myasthenia Gravis 1Hematologic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 59Cyclophosphamide 44pembrolizumab 34Radiotherapy 30fludarabine 27Nivolumab 26Biopsy 26Metformin 22Fluorodeoxyglucose F18 22Specimen Handling 20Bevacizumab 20Temozolomide 17Radiosurgery 17Cisplatin 16Carboplatin 14Fluorouracil 13Dexamethasone 13Paclitaxel 12Gemcitabine 12Etoposide 12gallium 68 PSMA-11 11durvalumab 11X-Rays 11Surgical Procedures, Operative 11Radiation 11Positron Emission Tomography Computed Tomography 11Letrozole 11Irinotecan 11Ipilimumab 11Surveys and Questionnaires 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × OTHER × Abatacept × Clear all
NCT06731504 2026-01-16

HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT

Duke University

Phase EARLY_PHASE1 Recruiting
10 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT03059888 2019-11-22

Trial of Orencia in Patients With Myasthenia Gravis

Johns Hopkins University

Phase EARLY_PHASE1 Terminated
6 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡